Active NRT showed no clear difference in abstinence at 6 months ‐ heterozygous or homozygous minor compared with placebo ‐ rs16969968 ‐ non‐Hispanic black or African American (low certainty).
Active NRT probably leads to lower abstinence at end of treatment ‐ heterozygous or homozygous minor compared with placebo ‐ rs16969968 ‐ non‐Hispanic black or African American (moderate certainty).
Active NRT showed no clear difference in end of treatment ‐ homozygous minor compared with placebo ‐ rs 588765 ‐ non‐Hispanic white (low certainty).
Active NRT showed no clear difference in 6‐Month abstinence ‐ heterozygous or homozygous minor compared with placebo ‐ rs2036527 ‐ non‐Hispanic black or African American (moderate certainty).
Active NRT showed no clear difference in end of treatment ‐ heterozygous or homozygous minor compared with placebo ‐ rs2036527 ‐ non‐Hispanic black or African American (moderate certainty).
It is very uncertain whether active NRT changes 6‐Month abstinence ‐ homozygous minor compared with placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white (very low certainty).
Active NRT showed no clear difference in end of treatment ‐ homozygous minor compared with placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white (low certainty).
Active NRT may leads to higher abstinence at end of treatment ‐ homozygous minor compared with placebo ‐ rs1051730 ‐ non‐Hispanic white (low certainty).
Active NRT showed no clear difference in end of treatment ‐ homozygous minor compared with placebo ‐ rs16969968 ‐ non‐Hispanic white (low certainty).
Desmopressin showed no clear difference in minor adverse events compared with placebo (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether desmopressin changes minor adverse events compared with alpha‐blocker (very low certainty).
It is very uncertain whether desmopressin plus alpha‐blocker changes minor adverse events compared with alpha‐blocker (very low certainty).
Desmopressin plus alpha‐blocker may leads to lower minor adverse events compared with alpha‐blocker plus anticholinergic (low certainty).
It is very uncertain whether macrolides changes minor adverse events compared with any other antibiotic (very low certainty).
It is very uncertain whether macrolide (erythromycin) changes minor adverse events compared with any other macrolide (very low certainty).
The review found no eligible studies for this question.